Journal
VACCINES
Volume 8, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/vaccines8030360
Keywords
HIV vaccine; HIVconsvX; HIVconsv; conserved regions; T cell vaccine; mRNA vaccines
Categories
Funding
- Medical Research Council (MRC) UK
- UK Department for International Development (DFID) under the MRC/DFID Concordat agreements [G1001757, MR/N023668/1]
- International AIDS Vaccine Initiative (IAVI)
- IAVI of the United States Agency for International Development (USAID)
- European Union [681137]
- MRC [MR/N023668/1] Funding Source: UKRI
Ask authors/readers for more resources
A vaccine will likely be one of the key tools for ending the HIV-1/AIDS epidemic by preventing HIV-1 spread within uninfected populations and achieving a cure for people living with HIV-1. The currently prevailing view of the vaccine field is to introduce protective antibodies, nevertheless, a vaccine to be effective may need to harness protective T cells. We postulated that focusing a T-cell response on the most vulnerable regions of the HIV-1 proteome while maximizing a perfect match between the vaccine and circulating viruses will control HIV-1 replication. We currently use a combination of replication-deficient simian (chimpanzee) adenovirus and poxvirus modified vaccinia virus Ankara to deliver bivalent conserved-mosaic immunogens to human volunteers. Here, we exploit the mRNA platform by designing tetravalent immunogens designated as HIVconsvM, and demonstrate that mRNA formulated in lipid nanoparticles induces potent, broad and polyfunctional T-cell responses in a pre-clinical model. These results support optimization and further development of this vaccine strategy in experimental medicine trials in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available